• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of novel therapy for malignant mesothelioma by controllingADCC activity.

Research Project

Project/Area Number 22590863
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Respiratory organ internal medicine
Research InstitutionTottori University

Principal Investigator

SHIMIZU Eiji  鳥取大学, 医学部, 教授 (50187449)

Co-Investigator(Kenkyū-buntansha) CHIKUMI Hiroki  鳥取大学, 医学部付属病院, 准教授 (90283994)
Project Period (FY) 2010 – 2012
Project Status Completed (Fiscal Year 2012)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords胸膜中皮腫 / 分子標的治療
Research Abstract

Most patients with malignant pleural mesothelioma (MPM) have a history of exposure to carcinogenic asbestos fibers, and the latent period of this disease is more than 40 years. Therefore, the numbers of the patients are now still increasing. Cetuximab is a chimeric mouse-human antibody directed against the extracellular domain of EGFRand has been shown remarkable effects for colorectal cancer and head and neck cancer. However, no published in vitro or in vivo studies have focused on the effect of cetuximab against MPM. In the present study, we found that cetuximab has potent anti-tumor activity against MPM in combination with the methods to enhance its immunological function, antibody-dependent cellular cytotoxicity (ADCC) activity. Our data indicate the important role of ADCC activity in the mechanism of action of cetuximab and underscore the promising potential of cetuximab as a new class of therapeutic agent for use against MPM.

Report

(4 results)
  • 2012 Annual Research Report   Final Research Report ( PDF )
  • 2011 Annual Research Report
  • 2010 Annual Research Report
  • Research Products

    (11 results)

All 2012 2010

All Journal Article (7 results) (of which Peer Reviewed: 7 results) Presentation (4 results)

  • [Journal Article] Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity2012

    • Author(s)
      Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E
    • Journal Title

      Cancer Biol Ther

      Volume: 13 Pages: 369-378

    • URL

      http://dx.doi.org/10.4161/cbt.19238

    • Related Report
      2012 Final Research Report
    • Peer Reviewed
  • [Journal Article] Diagnostic and Prognostic Impact of Serum Soluble UL16-Binding Protein 2 in Lung Cancer Patients2012

    • Author(s)
      Yamaguchi K, Chikumi H, Shimizu A, Takata M, Kinoshita N, Hashimoto K, Nakamoto M, Matsunaga S, Kurai J, Miyake N, Matsumoto S, Watanabe M, Yamasaki A, Igishi T, Burioka N, Shimizu E
    • Journal Title

      Cancer Science

      Volume: (in press) Issue: 8 Pages: 1405-1413

    • DOI

      10.1111/j.1349-7006.2012.02330.x

    • Related Report
      2012 Final Research Report
    • Peer Reviewed
  • [Journal Article] Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells2012

    • Author(s)
      Miyake N, Chikumi H, Takata M, Nakamoto M, Igishi T, Shimizu E
    • Journal Title

      Oncology reports 28

      Volume: 28 Pages: 848-854

    • URL

      http://www.ncbi.nlm.nih.gov/pubmed/22313637

    • Related Report
      2012 Final Research Report
    • Peer Reviewed
  • [Journal Article] Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma2012

    • Author(s)
      Kurai J, Chikumi HT, Hamada H, Yano S, , Hashimoto K, Takata M, Sako T, Yamaguchi K, Kinoshita N, Watanabe M, Touge H, Makino H, Igishi Shimizu E
    • Journal Title

      International Journal of Oncology

      Volume: 41 Issue: 5 Pages: 1610-1618

    • DOI

      10.3892/ijo.2012.1607

    • Related Report
      2012 Annual Research Report 2012 Final Research Report
    • Peer Reviewed
  • [Journal Article] Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells2012

    • Author(s)
      Miyake Naomi
    • Journal Title

      Oncology Reports

      Volume: 28 Issue: 3 Pages: 848-854

    • DOI

      10.3892/or.2012.1855

    • Related Report
      2012 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity2012

    • Author(s)
      Takata M, Shimizu E, et al
    • Journal Title

      Cancer biology & therapy

      Volume: 13 Pages: 369-378

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Diagnostic and Prognostic Impact of Serum Soluble UL16-Bin ding Protein 2 in Lung Cancer Patients2012

    • Author(s)
      Yamaguchi K, Shimizu E, et al
    • Journal Title

      Cancer Science

      Volume: 103(印刷中)

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Presentation] Circulating serum ULBP2 in patients with various lung diseases2012

    • Author(s)
      Kinoshita N, Chikumi H, Yamaguchi K, Takata M, Nakamoto M, Kodani M, Matsumoto S, Kawasaki Y, Tadashi I, Shimizu E
    • Organizer
      第52回日本呼吸器学会学術講演会
    • Place of Presentation
      神戸コンベンションセンター(神戸)
    • Year and Date
      2012-04-22
    • Related Report
      2012 Final Research Report 2011 Annual Research Report
  • [Presentation] Development of a novel combination therapy using cetuximab2012

    • Author(s)
      Takata M, Chikumi H, Igishi T, Burioka N, Yamasaki A, Nakamoto M, Kinoshita N, Kitaura T, Okada K, Shimizu E
    • Organizer
      第52回日本呼吸器学会学術講演会
    • Place of Presentation
      神戸コンベンションセンター(神戸)
    • Year and Date
      2012-04-20
    • Related Report
      2012 Final Research Report 2011 Annual Research Report
  • [Presentation] Antibody-dependent cellular cytotoxicity mediated by cetuximab against mesothelioma cells2010

    • Author(s)
      Chikumi H, Kurai J, Kinoshita N, Nakamoto M, Matsumoto S, Igishi T, Hamada H, Yano S, Shimizu E
    • Organizer
      The 10th international conference of the international mesothelioma interest group
    • Place of Presentation
      Kyoto, Japan
    • Year and Date
      2010-09-02
    • Related Report
      2012 Final Research Report
  • [Presentation] Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Mesothehoma Cells.2010

    • Author(s)
      H.Chikumi, E.Shimizu.
    • Organizer
      The 101th International Conference of the International Mesothelioma Interest Group.
    • Place of Presentation
      京都国際会議場(京都)
    • Year and Date
      2010-09-02
    • Related Report
      2010 Annual Research Report

URL: 

Published: 2010-08-23   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi